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Abstract: The incidence and outcome of group B streptococcal (GBS) 
sepsis were assessed prospectively between September 2011 and February 
2015 in all tertiary care pediatric hospitals of Switzerland. We describe a 
low incidence of GBS early-onset sepsis (0.12/1000 livebirths) and a pre-
dominance of GBS late-onset sepsis (0.36/1000 livebirths), a pattern that 
has not been reported in other countries.
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Streptococcus agalactiae or group B streptococcus (GBS) is among the most frequent pathogens causing sepsis during 
infancy.1 Because of differences in pathogenesis, clinical presenta-
tion and outcome, GBS disease is categorized into early-onset sep-
sis (EOS) and late-onset sepsis (LOS). After the implementation of 
intrapartum antibiotic prophylaxis (IAP), surveillance studies have 
reported a 50%–85% reduction of GBS-EOS, whereas the inci-
dence of GBS-LOS has remained stable.2 However, recent studies 
performed in the United States, Europe and Australia indicate that, 
despite the marked reduction associated with the recommendations 
for IAP, the incidence of GBS-EOS remains similar3,4 or higher1,5,6 
compared with the incidence of GBS-LOS. Yet, important geo-
graphical differences exist in the epidemiology of GBS disease and 
its prevention strategies.1,6 In this study, we assessed the incidence, 
clinical features and outcome of GBS sepsis over a 3.5-year period 
in Switzerland, a country where IAP is administered on the basis of 
maternal antepartum screening results, following the recommenda-
tions of the Centers for Disease Control and Prevention.3
PATIENTS AND METHODS
The Swiss Pediatric Sepsis Study prospectively investigates 
the epidemiology of blood culture–proven sepsis in children in all 
10 tertiary care pediatric hospitals of Switzerland. These centers host 
all neonatal and pediatric intensive care units of the country. Infants 
from birth to <1 year of age were eligible for this study if they devel-
oped bacteremia between September 2011 and February 2015, in the 
presence of a systemic inflammatory response syndrome, as defined 
by the consensus statement.7 Contaminations were excluded. Positive 
blood cultures were identified automatically by microbiology labora-
tory notification systems, and systemic inflammatory response was 
confirmed prospectively by clinicians. The study was approved by the 
ethics committees of all participating centers. Data on demograph-
ics, perinatal risk factors, infection focus, severity and outcome were 
recorded prospectively. EOS was defined as infection presenting 
<7 days of life, and LOS was defined as infection presenting ≥7 days. 
Each episode of sepsis was considered as a single case. The incidence 
of GBS sepsis was calculated for infants born at the study centers. 
We also calculated the national incidence of GBS sepsis, estimating 
that the participating centers admitted 75% of all infants treated for 
sepsis in Switzerland. The number of livebirths in Switzerland was 
obtained from the Swiss Federal Statistical Office.
Statistical analyses were performed using PRISM (Graph-
Pad Software Inc., La Jolla, CA). Baseline clinical characteristics 
were described by showing the median and the interquartile range 
(IQR) for continuous variables and numbers and percentages for 
categorical variables. Comparisons of continuous and categorical 
variables between cases of EOS and LOS were performed using 
2-tailed t tests and Pearson χ2 tests.
RESULTS
Five hundred thirty-nine episodes of blood culture–proven 
sepsis were diagnosed in infants during a 3.5-year period. GBS was 
the third most common pathogen with 14% (n = 74) of episodes. 
In comparison, Escherichia coli and coagulase-negative staphylo-
cocci were identified in 23% (n = 122) and 19% (n=103) of sepsis 
episodes, respectively. Among cases of GBS sepsis, 30% (n = 22) 
presented as EOS and 70% (n = 52) as LOS (Table 1). Four patients 
had recurrent GBS sepsis: 3 patients had 2 episodes of GBS-LOS 
and 1 patient had both GBS-EOS and GBS-LOS.
The total number of livebirths was 69,118 in the study cent-
ers and 289,543 in the whole country. The incidence of GBS-EOS 
and GBS-LOS was 0.12 [95% confidence interval (CI): 0.05–0.23] 
and 0.36/1000 livebirths (95% CI: 0.23–0.53), respectively, for 
infants born at the study centers. The estimated national incidence 
of GBS-EOS and GBS-LOS in Switzerland was 0.10 (95% CI: 
0.06–0.15) and 0.24/1000 livebirths (95% CI: 0.18–0.31), respec-
tively, which is not significantly different from the incidence at the 
study centers (P = 0.75 for EOS and 0.09 for LOS). In infants born 
<37 weeks of gestation, the estimated national incidence of GBS-
EOS and LOS was 0.36/1000 livebirths (95% CI: 0.16–0.78) and 
1.01/1000 livebirths (95% CI: 0.63–1.62), respectively. For infants 
born with a birth weight <1500 g, the estimated incidence of GBS-
EOS and LOS was 1.04/1000 livebirths (95% CI: 0.35–3.04) and 
3.80/1000 livebirths (95% CI: 2.12–6.79), respectively.
Among patients with GBS-EOS, 73% (16/22) presented 
with clinical signs on the first day of life and 91% (20/22) presented 
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within the first 2 days of life. For LOS, the median age at clinical 
presentation was 34 days (IQR: 18–58). Of note, 12% (6 of 52) of 
infants with GBS-LOS presented beyond 90 days of age, between 
91 and 202 days. In our entire cohort of children younger than 
17 years with blood culture–proven sepsis, no patient presented 
with GBS sepsis at an age >202 days.
The median gestational age at birth was 39 1/7 weeks (IQR: 
35–41) for patients with EOS and 39 weeks (IQR: 33–40) for those 
with LOS. The median birth weight was 3150 g (IQR: 2190–3510) 
for EOS and 3000 g (IQR: 2230–3330) for LOS. Maternal GBS sta-
tus was unknown to the obstetrical team at the time of birth in 12% 
(9 of 74) of cases of GBS sepsis. Of the mothers who were screened 
for GBS, 42% (27 of 65) were positive, but only 48% (13 of 27) of 
them received IAP. Eleven (21%) episodes of GBS-LOS occurred 
after >2 days of hospitalization. All (11 of 11) infants with hospital-
acquired GBS-LOS were preterm, whereas 15% (6 of 41) of infants 
with community-acquired GBS-LOS were preterm.
In 70% of infants (n = 52), GBS sepsis presented as bacte-
remia without a focus. All GBS strains were susceptible to penicil-
lin. Patients with GBS-EOS were more likely to present with sep-
tic shock than patients with GBS-LOS, and they more frequently 
required noninvasive and/or invasive ventilation. Two (3%) infants 
with GBS sepsis died: an infant born at 29 6/7 weeks of gestation 
died on the first day of life because of GBS septic shock; a term 
infant with GBS-EOS died at 4 weeks of age because of complica-
tions of a congenital heart disease.
DISCUSSION
We report on prospective national surveillance of GBS blood 
culture–proven sepsis in Switzerland. This study confirms that GBS 
remains among the top 3 causes of sepsis in infants, together with 
Escherichia coli and coagulase-negative staphylococci. Our results 
show a strong predominance of GBS-LOS over GBS-EOS in Swit-
zerland. This pattern, which has not been described in other coun-
tries, is because of a particularly low incidence of GBS-EOS in 
Switzerland. Indeed, the incidence of GBS-EOS in our cohort is 
2- to 4-fold lower than the incidence reported in other high-income 
countries, whereas the incidence of GBS-LOS is in the range of 
previous studies performed in other European countries, Australia 
and North America.1,4–6,8
The reason for a low incidence of GBS-EOS in Switzerland 
is unclear. National data on the rate of rectovaginal GBS carriage 
in pregnant women and IAP are not available in Switzerland. How-
ever, low rates of colonization are unlikely as GBS carriage was 
identified in 16% of pregnant women in a Swiss hospital, which is 
comparable with reports from other countries.9 In all centers partic-
ipating in our study, IAP was administered based on routine screen-
ing of pregnant women for GBS, as recommended by the Cent-
ers for Disease Control and Prevention.3 Yet, the proportion of all 
GBS-positive mothers who received IAP was not recorded in our 
study. Only half of the infants with GBS sepsis who were born to 
GBS-positive mothers were exposed to IAP. This shows that missed 
opportunities for prevention still exist. Reinforcing the implemen-
tation of maternal GBS screening and improving the compliance 
to administration of IAP could lead to a further decrease in the 
incidence of GBS-EOS in Switzerland.
In agreement with the previous studies, the majority of 
infants with EOS presented within the first 24 hours and almost 
all (91%) within the first 2 days of life. Interestingly, 12% of the 
GBS-LOS cases presented after 90 days of age, indicating that the 
vulnerability to invasive GBS disease remains high throughout the 
first year of life.
With a 1.4% direct GBS-related fatality rate, the overall 
mortality was lower in our cohort compared with other studies that 
reported a 4.6% fatality rate.1 However, disease severity was consid-
erable with 23% of cases requiring invasive ventilation and 12% pre-
senting with septic shock. Disease severity was greater in EOS com-
pared with LOS, which may reflect an exposure to a higher bacterial 
load perinatally, less-efficient host defenses and/or a lower functional 
reserve of vital organs during adaptation to extrauterine life.
TABLE 1. Baseline Demographics and Outcomes of Blood Culture–proven Group B 
Streptococcal Sepsis in Infants Admitted to the 10 Tertiary Care Pediatric Hospitals of 
Switzerland
Early-onset Sepsis Late-onset Sepsis P Value
Number of cases (%) 22 (29) 52 (70)
Incidence in inborns* per 1000 livebirths (95% CI) 0.12 (0.05–0.23) 0.36 (0.23–0.53) 0.003
Estimated incidence per 1000 livebirths (95% CI) 0.10 (0.06–0.15) 0.24 (0.18–0.31) <0.001
Maternal GBS status, n (%)
  Positive 8 (36) 19 (37) 0.56
  Negative 10 (45) 28 (54)
  Unknown 4 (18) 5 (10)
Intrapartum antibiotic prophylaxis, n (%) 5 (23) 14 (27) 0.71
Male gender, n (%) 9 (41) 29 (56) 0.24
Median gestational age at birth, wk (IQR) 39 (35–41) 39 (33–40) 0.49
Prematurity, n (%) 6 (27) 17 (33) 0.65
Median birth weight, g (IQR) 3150 (2190–3510) 3000 (2230–3330) 0.37
Median age at presentation, d (IQR) 0 (0–0) 34 (18–58)
Median time to positivity of blood cultures, h (IQR) 15.3 (8.5–20.2) 12.0 (9.4–28.6) 0.34
Mortality, n (%) 2 (10) 0
Septic shock,† n (%) 6 (27) 3 (6) 0.009
Noninvasive ventilation, n (%) 8 (36) 8 (15) 0.04
Invasive ventilation, n (%) 8 (36) 9 (17) 0.04
Focus of infection, n (%)
  Bacteremia without a focus 17 (77) 35 (67) 0.39
  Meningitis 4 (18) 9 (17) 0.93
  Pneumonia 1 (5) 2 (4) 0.89
  Cellulitis 0 5 (10)
*Includes only infants born at the 10 participating centers.
†As defined in the study by Goldstein et al.7
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A limitation of this study is related to the fact that we 
included only the episodes of GBS disease with positive blood cul-
tures. Previous reports indicate that 13%–38% of infants with GBS 
meningitis have negative blood cultures. Therefore, our study may 
underestimate the total burden of GBS invasive disease.4,5,8 A second 
limitation is that the surveillance, which was based on the 10 main 
pediatric hospitals of Switzerland, may have missed some cases with 
milder clinical presentation that were treated in regional hospitals. 
However, because all neonatal and pediatric intensive care units of 
Switzerland participated in this study, we can assume that all severe 
cases were captured. The estimated national incidence was not dif-
ferent from the incidence of GBS sepsis calculated for the infants 
born at the participating centers, suggesting that our study is provid-
ing a robust estimate of the epidemiology of GBS sepsis in Switzer-
land. The long-term consequences of GBS sepsis were not evaluated 
in our cohort, but it is well known that neonatal sepsis and menin-
gitis are associated with adverse neurodevelopmental outcomes.10
In conclusion, we describe a low incidence of GBS-EOS 
in Switzerland, with a predominance of GBS-LOS. These find-
ings confirm that the incidence of GBS sepsis varies considerably 
between high-income countries.1 Our results highlight the need for 
epidemiological surveillance of GBS disease and warrant for caution 
when extrapolating data to other populations. Despite large efforts 
to reduce the impact of GBS disease, GBS continues to cause sig-
nificant burden on neonatal and infant health. Better strategies are 
required for the prevention of both early- and late-onset GBS disease.
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